Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 624-632

  Yu, ZHeng He ^a   Jiang, Hai Yin ^b   Shao, Li ^b   Zhou, Yuan Yue ^c,d   Shi, Hai Yan ^b   Ruan, Bing ^b  

^a HANGZHOU SEVENTH PEOPLE S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Seventh Hospital of Hangzhou   (China)

Author keywords

antipsychotic agents; coronary disease; myocardial infarction

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEMENTIA; DOSE RESPONSE; HEART INFARCTION; HUMAN; INCIDENCE; META ANALYSIS; MOOD DISORDER; OBSERVATIONAL STUDY; ODDS RATIO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84982933519     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12985     Document Type: Review

References (38)

1. Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ 2014; 348: g1173.
2. Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand 2014; 130: 452–69.
3. Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 2014; 28: 989–1003.
4. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 2013; 3: CD007726.
5. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007; CD005594.
6. Ryu S, Yoo JH, Kim JH, Choi JS, Baek JH, Ha K, et al. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. J Clin Psychopharmacol 2015; 35: 13–21.
7. Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 2012; 201: 52–6.
8. Nose M, Recla E, Trifiro G, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2015; 24: 812–20.
9. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192: 406–11.
10. Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatr 2015; 14: 56–63.
11. Brauer R, Douglas I, Smeeth L. The association between antipsychotic agents and the risk of myocardial infarction: a systematic review. Br J Clin Pharmacol 2011; 72: 871–8.
12. Nakagawa S, Pedersen L, Olsen ML, Mortensen PB, Sorensen HT, Johnsen SP. Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. J Intern Med 2006; 260: 451–8.
13. Thorogood M, Cowen P, Mann J, Murphy M, Vessey M. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992; 340: 1067–8.
14. Penttinen J, Valonen P. Use of psychotropic drugs and risk of myocardial infarction: a case-control study in Finnish farmers. Int J Epidemiol 1996; 25: 760–2.
15. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996; 94: 3123–9.
16. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004; 192: 19–27.
17. Pariente A, Fourrier-Reglat A, Ducruet T, Farrington P, Beland SG, Dartigues JF, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med 2012; 172: 648–53.discussion 54-5
18. Lin ST, Chen CC, Tsang HY, Lee CS, Yang P, Cheng KD, et al. Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation 2014; 130: 235–43.
19. Brauer R, Smeeth L, Anaya-Izquierdo K, Timmis A, Denaxas SC, Farrington CP, et al. Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J 2015; 36: 984–92.
20. Wu SI, Kao KL, Chen SC, Juang JJ, Lin CJ, Fang CK, et al. Antipsychotic exposure prior to acute myocardial infarction in patients with serious mental illness. Acta Psychiatr Scand 2015; 131: 213–22.
21. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12.
22. Higgins. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration. [online]. Available at: http://www.cochrane-handbook.org (last accessed 6 December 2014).
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
25. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 2013; 39: 295–305.
26. Zeng C, Asico LD, Wang X, Hopfer U, Eisner GM, Felder RA, et al. Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR. Hypertension 2003; 41: 724–9.
27. Yu C, Yang Z, Ren H, Zhang Y, Han Y, He D, et al. D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs. Am J Hypertens 2009; 22: 877–83.
28. Huang H, Han Y, Wang X, Chen C, Yu C, He D, et al. Inhibitory effect of the D(3) dopamine receptor on insulin receptor expression and function in vascular smooth muscle cells. Am J Hypertens 2011; 24: 654–60.
29. Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf 2014; 37: 79–90.
30. De Keyser J, De Waele M, Convents A, Ebinger G, Vauquelin G. Identification of D1-like dopamine receptors on human blood platelets. Life Sci 1988; 42: 1797–806.
31. Ricci A, Bronzetti E, Mannino F, Mignini F, Morosetti C, Tayebati SK, et al. Dopamine receptors in human platelets. Naunyn Schmiedebergs Arch Pharmacol 2001; 363: 376–82.
32. Yamada S, Akita H, Kanazawa K, Ishida T, Hirata K, Ito K, et al. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis 2000; 150: 143–8.
33. Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2009; 42: 66–71.
34. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22: 413–30.
35. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697–701.
36. Lee TM, Lin SZ, Chang NC. Antiarrhythmic effect of lithium in rats after myocardial infarction by activation of Nrf2/HO-1 signaling. Free Radic Biol Med 2014; 77: 71–81.
37. Olfson M, King M, Schoenbaum M. Treatment of Young People With Antipsychotic Medications in the United States. JAMA Psychiatr 2015; 72: 867–74.
38. Oh SW, Kim J, Myung SK, Hwang SS, Yoon DH. Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies. Br J Clin Pharmacol 2014; 78: 727–37.